跳到正文
原文
Journal of Clinical Oncology 临床肿瘤· Nilofer S. Azad·· 1 小时前AI 评分55

COMPANION-002:Tovecimig联合紫杉醇与单独紫杉醇作为二线疗法治疗晚期胆道癌的II/III期随机对照试验

COMPANION-002: A Randomized Phase II/III Trial of Tovecimig Plus Paclitaxel Versus Paclitaxel Alone as a Second-Line Therapy in Patients With Advanced Biliary Tract Cancer

AI 导读

COMPANION-002试验对比了Tovecimig联合紫杉醇与单独紫杉醇作为二线疗法治疗晚期胆道癌的效果,是一项II/III期随机对照试验。

来源:Journal of Clinical Oncology 临床肿瘤 · ascopubs.org